Browse the evidence

Endogenous GIP acts as an incretin that potentiates glucose-stimulated insulin secretion, and its inhibition via GIP receptor antagonists reveals this physiological role.

GIP naturally helps your body release insulin after eating. Early treatments tried adding more GIP, but it didn't work well in diabetics. New research shows that blocking GIP's natural signal helps scientists understand its true role, which is still to boost insulin, even in diabetes.

Tirzepatide is associated with a significantly higher incidence of gastrointestinal adverse events (nausea, vomiting, diarrhea, decreased appetite) compared to placebo, insulin, and GLP-1 RAs, particularly at higher doses.

Expect gastrointestinal side effects like nausea and diarrhea, especially when starting or increasing the dose. These are common but often improve over time. Discuss management strategies with your doctor.

Higher fasting insulin levels and lower Sex Hormone-Binding Globulin (SHBG) levels causally increase the risk of PCOS, acting as key metabolic drivers of the syndrome.

Managing insulin resistance is crucial for PCOS prevention and management. High insulin and low SHBG are causal factors. Lifestyle interventions that improve insulin sensitivity (diet, exercise) can mitigate PCOS risk by addressing these metabolic drivers.

GLP-1 receptor ligands reduce cardiovascular mortality and major adverse cardiovascular events in patients with type 2 diabetes, with efficacy varying by specific drug half-life and homology to native GLP-1.

If you have type 2 diabetes and cardiovascular risk, GLP-1 receptor ligands like semaglutide or liraglutide can significantly reduce your risk of heart-related death and events. However, not all GLP-1 drugs offer this specific heart protection; shorter-acting versions may not provide the same benefit. Consult your doctor to ensure you are prescribed a GLP-1 agent with proven cardiovascular outcomes.

Obesity is a neurobiological disorder driven by genetic and environmental interactions that dysregulate brain-controlled energy homeostasis, rather than a failure of individual willpower.

Understand that obesity is a complex biological condition influenced by genetics and environment, not a simple failure of willpower. This perspective shifts the focus from self-blame to seeking effective, biologically-targeted treatments and lifestyle adjustments that work with your body's natural regulatory systems.

Hyperglycemia and insulin resistance drive Coronary Microvascular Dysfunction (CMD) through oxidative stress, inflammation, and reduced nitric oxide (NO) bioavailability, leading to endothelial dysfunction.

Controlling blood sugar and insulin resistance is critical not just for nerves and kidneys, but for heart health. High glucose and insulin resistance directly damage the heart's small blood vessels by creating oxidative stress and reducing the body's ability to dilate blood vessels (NO bioavailability).

GLP-1 receptor agonists are associated with an increased risk of gastrointestinal side effects (nausea, vomiting, diarrhea) and rare serious adverse events (gallbladder disorders, pancreatitis), as well as emerging risks related to delayed gastric emptying affecting anesthesia and endoscopy.

Be aware that nausea, vomiting, and diarrhea are common when starting GLP-1 medications, but they often improve over time. Serious side effects like gallbladder issues or pancreatitis are rare but require medical attention. If you need surgery or a colonoscopy, inform your provider, as they may need to adjust your medication schedule to prevent complications like aspiration.

Exercise mimetics fail to replicate exercise's cardiovascular benefits because they do not address the hemodynamic stimuli (shear stress, pressure) that directly regulate arterial health and endothelial function.

Exercise benefits the heart and arteries through mechanical forces (blood flow, pressure) that pills cannot replicate. This is why exercise remains superior for cardiovascular health compared to any current pharmacological intervention.

GLP-1 receptor agonists provide significant cardiorenal protection, reducing major adverse cardiovascular events (MACE) and kidney-related complications in patients with type 2 diabetes and/or cardiovascular disease, independent of weight loss.

GLP-1 medications do more than help you lose weight; they actively protect your heart and kidneys. For people with diabetes or existing heart/kidney issues, these drugs significantly lower the risk of heart attacks, strokes, and kidney failure. This protection is a key reason why doctors prescribe them, offering benefits beyond just the scale.

Enteroendocrine cells (EECs) act as chemosensors that secrete hormones (e.g., GLP-1, PYY, CCK) in response to luminal nutrients, regulating appetite, glucose metabolism, and gut motility.

Your gut contains specialized cells that sense what you eat and send signals to your brain and pancreas to regulate hunger and blood sugar. This natural system can be targeted by medications to treat metabolic diseases.

Long-term weight loss maintenance is physiologically opposed by metabolic adaptation (reduced energy expenditure) and hyperphagia (increased appetite), driven by neuroendocrine signals like leptin, making weight regain the default biological state.

Understand that after weight loss, your body biologically fights to regain weight through increased hunger and slower metabolism. This is not a failure of willpower but a physiological defense. Successful maintenance requires acknowledging this biological reality and often necessitates ongoing, lifelong behavioral or medical support to counter these natural drives.

Loss-of-function mutations in the central melanocortin system (specifically MC4R, POMC, or AgRP pathways) consistently increase fat preference and decrease carbohydrate preference in both rodents and humans.

For individuals with specific genetic variants affecting the melanocortin system, there is a biological predisposition toward higher fat preference and lower carbohydrate preference. Recognizing this can help in selecting dietary strategies that align with these preferences or manage them through environmental control.

The hypothalamus regulates body fat mass through a defended set point, where afferent signals from gut hormones (GLP-1, CCK, ghrelin) and adipose tissue (leptin) modulate food intake and energy expenditure.

Your brain uses signals from your gut (like GLP-1 and ghrelin) and fat cells (leptin) to decide how hungry you are and how much energy you burn. In obesity, this system is broken, defending a higher weight.

Obesity is a chronic disease driven by pathophysiologic dysregulation of energy balance (neural, hormonal, metabolic pathways), not merely a behavioral failure of discipline.

Stop blaming yourself for your weight. Your body's biology (hormones, brain signals) is actively fighting weight loss. This is a medical condition, not a moral failure. Effective treatment requires addressing the biology, not just 'trying harder'.

Obesity is a chronic disease characterized by physiological dysregulation of fat mass, not merely a result of willful behavioral choices.

Stop blaming yourself for your weight. Obesity is a chronic disease driven by your body's physiology, not just your willpower. Seek medical treatment because your body is fighting you, and you need professional help to manage it.

SGLT2 inhibitors improve cardiovascular outcomes in heart failure patients, including those with preserved and reduced ejection fraction, independent of diabetes status.

If you have heart failure, ask your doctor about SGLT2 inhibitors. They are now recommended for heart failure patients regardless of whether they have diabetes, as they significantly improve outcomes.

Resmetirom, a THR-β agonist, improves histologic features of MASLD, including resolution of steatohepatitis without worsening fibrosis and improvement in fibrosis stage, in patients with F1-F3 fibrosis.

Resmetirom is the first FDA-approved drug for MASH. In clinical trials, doses of 80mg or 100mg taken daily for 52 weeks significantly improved liver inflammation and fibrosis compared to placebo. It is an option for those with F1-F3 fibrosis.

Obesity is a chronic, highly heritable neurological disease driven by central nervous system regulation of satiety and reward, rather than solely a behavioral failure of willpower.

Obesity is a biological condition involving brain pathways that control hunger and reward, heavily influenced by genetics. This means it is not simply a failure of willpower. Effective management often requires addressing these biological drivers, potentially through medical therapies that target these specific pathways, rather than relying solely on lifestyle changes which may be insufficient for those with high genetic risk.

GLP-1 receptor agonists provide significant cardiovascular risk reduction in both diabetic and non-diabetic patients with established cardiovascular disease, a benefit that is significantly under-recognized by physicians, particularly for non-diabetic patients.

For patients with obesity and established cardiovascular disease, GLP-1 agonists offer significant cardiovascular risk reduction (20% reduction in MACE in non-diabetics). Prescribers should be aware of these benefits to ensure appropriate patient selection and counseling, regardless of diabetic status.

The gut pathobiont Bilophila wadsworthia acts as a glycine sink by metabolizing glycine via the glycine reductase pathway, thereby lowering circulating glycine levels and negatively impacting metabolic markers.

The presence of the gut bacteria Bilophila wadsworthia consumes glycine, reducing its beneficial effects. Vegan diets tend to reduce this bacteria, thereby increasing glycine. While probiotics targeting this specific bacteria are not yet standard, understanding this link highlights why microbiome composition matters for metabolic health.

MASLD is an independent risk factor for cardiovascular disease, including heart failure (particularly HFpEF), atrial fibrillation, and atherosclerosis, driven by shared mechanisms like insulin resistance and inflammation.

If you have fatty liver disease (MASLD), you are at a significantly higher risk for heart problems, including heart failure and atrial fibrillation, even if your liver enzymes are normal. This risk is driven by the same metabolic issues that cause fatty liver. You need regular cardiovascular screening and aggressive management of blood pressure, cholesterol, and blood sugar to protect your heart.

GLP-1 receptor agonists are associated with gastrointestinal side effects (nausea, vomiting, diarrhea) and potentially increased risks of pancreatitis and thyroid cancer.

GLP-1 agonists commonly cause GI issues like nausea and diarrhea, especially when starting or increasing the dose. Serious but rare risks include pancreatitis and thyroid cancer. Monitor your health and report severe symptoms to your doctor.

GLP-1 based therapies carry class-wide safety warnings including gastrointestinal effects, gallbladder events, pancreatitis risk, and a boxed warning for medullary thyroid carcinoma based on rodent data.

These medications work well but can cause nausea, vomiting, or other GI issues. Your doctor will start you on a low dose and slowly increase it to help your body adjust. If you have a family history of specific thyroid cancers, you cannot take these drugs.

Tight glycemic control (HbA1c ≤ 6.5%) in Type 2 Diabetes does not significantly reduce major cardiovascular events or all-cause mortality compared to standard control, and may increase mortality and hypoglycemia risk.

For Type 2 Diabetics, aiming for an A1c of 7% or slightly higher (if safe) is often as effective for heart protection as aiming for very low numbers (≤6.5%), while avoiding the risks of severe hypoglycemia and weight gain. Focus on overall cardiovascular risk management (blood pressure, lipids) rather than obsessing over ultra-tight glucose control, unless you are newly diagnosed with Type 1 Diabetes.